Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • IS OBESITY AND HYPERURICEMIA RELATED WITH THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE?

Surprisingly Fast Transport in Carbon Nanotube Membranes Could Advance Human Health

Interspecies chimerism and cell survival- vulnerable due to cell competition!

IS OBESITY AND HYPERURICEMIA RELATED WITH THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE?
  • BiotechToday
  • World

IS OBESITY AND HYPERURICEMIA RELATED WITH THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE?

bioxone February 13, 2021February 12, 2021

Shrestha Dutta, Amity University Kolkata

Non-alcoholic fatty liver disease (NAFLD) is the most quickly spreading chronic liver sickness. It is closely identified with metabolic disorder and its related conditions, including obesity, type 2 diabetes, dyslipidemia, hypertension, and hyperuricemia. Past studies have uncovered a connection between hyperuricemia and the seriousness of liver damage in NAFLD. A biopsy-based analysis has shown that hyperuricemia is related to the seriousness of steatosis, lobular infection, and nonalcoholic fatty liver disease activity score (NAS). Obesity is a dangerous factor for the development of NAFLD.

Recent studies uncover that body mass index (BMI) is a significant factor in the study of uric acid and metabolic diseases. According to the studies, researchers show that uric acid has no impact on the risk of ischemic heart disease and blood pressure. Hence, it is important to consider obesity to find the relation between hyperuricemia and NAFLD, especially in liver fibrosis. The goal of this research was to study whether obesity can alter the relationship between serum uric acid and the seriousness of liver damage in NAFLD, and the interactive impact of hyperuricemia and obesity.

Taking into account, BMI is a significant element in the study of uric acid and metabolic diseases, the relationship between hyperuricemia and the severity of NAFLD was additionally found in non-obese and obese people. Surprisingly, the relation was essentially changed in various BMI groups. In non-obese people, scientists found no proof of the relationship of hyperuricemia with either severe hepatic steatosis, raised ALT, or progressed fibrosis. Conversely, hyperuricemia was related to higher chances of both severe hepatic steatosis, raised ALT, and advanced fibrosis in obese NAFLD.

The outcomes uncovered that hyperuricemia was related to the seriousness of liver damage in obese NAFLD, not in non-obese people. Also, hyperuricemia and obesity had an essentially synergistic impact on hepatic steatosis and fibrosis. Hence, the board of uric acid should be focused on obese NAFLD.

Also read: Surprisingly Fast Transport in Carbon Nanotube Membranes Could Advance Human Health

Reference :Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease– Mimi Zhou et al,

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Hypertension hyperuricemia hyperuricemia and non-alcoholic fatty liver disease non-alcoholic fatty liver uric acid level obesity and BMI range obesity and diabetes obesity and hypertension

One thought on “IS OBESITY AND HYPERURICEMIA RELATED WITH THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE?”

  1. Pingback: Interspecies chimerism and cell survival- vulnerable due to cell competition! - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Interspecies chimerism and cell survival- vulnerable due to cell competition!

bioxone February 14, 2021

Ayooshi Mitra, Amity University, Kolkata Interspecies chimeras provide a unique platform for discovery and clinical use by probing early embryogenesis and regeneration. Interspecies chimeras are useful through interspecies blastocyst complementation to study human development and disease and also to produce functional human tissues. Cell competition involves a preserved fitness-sensing process during which adjoining less-fit but viable […]

chimerism

Related Post

  • BiotechToday
  • India

COVID UPDATE: Decrease in daily active cases in India

bioxone October 13, 2020October 13, 2020

Camelia Bhattacharyya, Amity University Kolkata The coronavirus, or the virus which has resulted in the whole world to shutdown, the ecosystem to change and us to depend completely on technology (to manage the economic conditions) and their immunity (since its more or less the survival of the fittest) first started its game in Wuhan, China. […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

High-Grade Serous Ovarian Carcinoma & its radical treatment

bioxone August 7, 2021August 6, 2021

Srabani Roy Chowdhury (MAKAUT, WB) HGSC or High-Grade Serous Ovarian Carcinoma is considered to be an aggressive type of ovarian cancer. Deleterious mutations present in the DNA repair gene RAD51C are drivers of defective homologous recombination in High-Grade Serous Ovarian Carcinoma (HGSC). These are emerging biomarkers of PARP inhibitor sensitivity. A PARP inhibitor is targeted […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A relaxin based nanoparticle treats liver fibrosis

bioxone January 29, 2021January 29, 2021

PRIYANKA CHAKRABORTY, AMITY UNIVERSITY, KOLKATA Liver fibrosis is one of the leading causes of morbidity and mortality among human beings. The unavailability of proper antifibrotic therapy makes the disease more deadly and the patients more vulnerable. RLX ( peptide hormone human relaxin-2), acting through a G protein-coupled receptor relaxin peptide receptor 1 (RXFP1), promotes tissue […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy